Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 4.67 AUD 1.74% Market Closed
Market Cap: 379.4m AUD
Have any thoughts about
Mayne Pharma Group Ltd?
Write Note

Mayne Pharma Group Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mayne Pharma Group Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Mayne Pharma Group Ltd
ASX:MYX
Total Current Assets
AU$460.6m
CAGR 3-Years
3%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Recce Pharmaceuticals Ltd
ASX:RCE
Total Current Assets
AU$5.1m
CAGR 3-Years
-38%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Total Current Assets
AU$228m
CAGR 3-Years
129%
CAGR 5-Years
66%
CAGR 10-Years
26%
Botanix Pharmaceuticals Ltd
ASX:BOT
Total Current Assets
AU$82.9m
CAGR 3-Years
57%
CAGR 5-Years
74%
CAGR 10-Years
42%
Probiotec Ltd
ASX:PBP
Total Current Assets
AU$72.6m
CAGR 3-Years
-5%
CAGR 5-Years
4%
CAGR 10-Years
13%
Arovella Therapeutics Ltd
ASX:ALA
Total Current Assets
AU$13.2m
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
N/A
No Stocks Found

Mayne Pharma Group Ltd
Glance View

Market Cap
379.4m AUD
Industry
Pharmaceuticals

Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.

MYX Intrinsic Value
8.02 AUD
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Mayne Pharma Group Ltd's Total Current Assets?
Total Current Assets
460.6m AUD

Based on the financial report for Jun 30, 2024, Mayne Pharma Group Ltd's Total Current Assets amounts to 460.6m AUD.

What is Mayne Pharma Group Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
0%

Over the last year, the Total Current Assets growth was -17%. The average annual Total Current Assets growth rates for Mayne Pharma Group Ltd have been 3% over the past three years .

Back to Top